Sanofi SA said the company would sell its stake in Regeneron Pharmaceuticals Inc., but would not change their ongoing collaboration.
Regeneron Pharmaceuticals will repurchase about $5 billion of the U.S. drugmaker’s shares directly from France’s Sanofi, without altering their 17-year partnership.
Maryland-based Novavax snagged $384 in additional grant funding to advance the company’s vaccine candidate against COVID-19.
AcelRx Pharmaceuticals of Redwood City, California, is buying Watertown, Massachusetts-based TetraPhase Pharmaceuticals for $14.4 million.
Launching an initial public offering (IPO) the same week the stock market plunged 1,190 in a single day may just be bad luck, but it does not seem to have negatively affected Passage Bio’s IPO.
Although there were some deals announced at the ongoing J.P. Morgan Healthcare Conference, biotech stocks appeared to slide slightly at the overall lack of business transactions, at least during the first day or two.
Bristol-Myers Squibb Co. and Celgene Corp. won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla.
Foamix Pharmaceuticals is merging with Menlo Therapeutics to become a biopharma company focusing on dermatology.
Halozyme Therapeutics is restructuring after halting development of a metastatic pancreatic cancer drug that failed to demonstrate an improvement in overall survival in a Phase III trial.
UCB will acquire U.S.-based Ra Pharmaceuticals in a $2.1 billion deal that will enable the Belgian drugmaker to offer new treatment options for several rare diseases in neurology and immunology.